Let the Guard Down: cAMP Activators Can Improve Immunotherapy in GBM.
| Autor: | Lee J; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio., Kay KE; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.; Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio., Vogelbaum MA; Department of NeuroOncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Lathia JD; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.; Case Comprehensive Cancer Center, Cleveland, Ohio.; Rose Ella Burkhardt Brain Tumor Center, Cleveland Clinic, Cleveland, Ohio. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cancer immunology research [Cancer Immunol Res] 2023 Oct 04; Vol. 11 (10), pp. 1300-1301. |
| DOI: | 10.1158/2326-6066.CIR-23-0667 |
| Abstrakt: | Enhancing T-cell infiltration into glioblastoma (GBM) tumors has proven challenging yet remains crucial for improving the efficacy of immunotherapy for patients with this deadly cancer. In this issue, Qin, Huang, Li, and colleagues find that inhibiting vasculature formation driven by cancer stem cells is a promising target to enhance immunotherapy in GBM. See related article by Qin, Huang, Li, et al., p. 1351 (2). (©2023 American Association for Cancer Research.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|